39728451|t|Mass Spectrometry Imaging Reveals Spatial Metabolic Alterations and Salidroside's Effects in Diabetic Encephalopathy.
39728451|a|Background: Diabetic encephalopathy (DE) is a neurological complication of diabetes marked by cognitive decline and complex metabolic disturbances. Salidroside (SAL), a natural compound with antioxidant and neuroprotective properties, has shown promise in alleviating diabetic complications. Exploring the spatial metabolic reprogramming in DE and elucidating SAL's metabolic effects are critical for deepening our understanding of its pathogenesis and developing effective therapeutic strategies. Methods: Air-flow-assisted desorption electrospray ionization-mass spectrometry imaging (AFADESI-MSI) was employed to investigate spatial metabolic alterations in the brains of db/db mice, a spontaneous DE model. The mice were treated with SAL (30 and 150 mg/kg, orally) for 12 weeks. Differential metabolites were identified and characterized using high-resolution mass spectrometry and validated against public databases. Results: Our AFADESI-MSI analysis revealed significant changes in 26 metabolites in the brains of DE mice compared to the controls. These metabolic changes indicated disruptions in glucose, glutamate-glutamine, nucleotide, lipid, choline, aspartate, and L-carnitine metabolism. Notably, glucose 6-phosphate (G6P), glutamine, adenosine, L-carnitine, and choline exhibited similar trends in both db/db mice and STZ-induced rat models of DE, suggesting their potential as reliable biomarkers. Twelve weeks of SAL treatment demonstrated a positive regulatory effect on glucose metabolism, the glutamate-glutamine cycle, and lipid metabolism. Conclusions: This study identifies key metabolic alterations in DE and demonstrates the therapeutic potential of SAL in modulating these disturbances, offering valuable insights for targeted interventions in diabetic complications.
39728451	42	51	Metabolic	Disease	MESH:D008659
39728451	68	79	Salidroside	Chemical	MESH:C009172
39728451	93	116	Diabetic Encephalopathy	Disease	MESH:C000721848
39728451	130	153	Diabetic encephalopathy	Disease	MESH:C000721848
39728451	155	157	DE	Disease	MESH:C000721848
39728451	164	189	neurological complication	Disease	MESH:D002493
39728451	193	201	diabetes	Disease	MESH:D003920
39728451	212	229	cognitive decline	Disease	MESH:D003072
39728451	242	251	metabolic	Disease	MESH:D008659
39728451	266	277	Salidroside	Chemical	MESH:C009172
39728451	279	282	SAL	Chemical	MESH:C009172
39728451	386	408	diabetic complications	Disease	MESH:D048909
39728451	432	441	metabolic	Disease	MESH:D008659
39728451	459	461	DE	Disease	MESH:C000721848
39728451	478	481	SAL	Chemical	MESH:C009172
39728451	484	493	metabolic	Disease	MESH:D008659
39728451	754	763	metabolic	Disease	MESH:D008659
39728451	799	803	mice	Species	10090
39728451	819	821	DE	Disease	MESH:C000721848
39728451	833	837	mice	Species	10090
39728451	856	859	SAL	Chemical	MESH:C009172
39728451	1138	1140	DE	Disease	MESH:C000721848
39728451	1141	1145	mice	Species	10090
39728451	1178	1187	metabolic	Disease	MESH:D008659
39728451	1221	1228	glucose	Chemical	MESH:D005947
39728451	1230	1239	glutamate	Chemical	MESH:D018698
39728451	1240	1249	glutamine	Chemical	MESH:D005973
39728451	1251	1261	nucleotide	Chemical	MESH:D009711
39728451	1263	1268	lipid	Chemical	MESH:D008055
39728451	1270	1277	choline	Chemical	MESH:D002794
39728451	1279	1288	aspartate	Chemical	MESH:D001224
39728451	1294	1305	L-carnitine	Chemical	MESH:D002331
39728451	1327	1346	glucose 6-phosphate	Chemical	MESH:D019298
39728451	1348	1351	G6P	Chemical	MESH:D019298
39728451	1354	1363	glutamine	Chemical	MESH:D005973
39728451	1365	1374	adenosine	Chemical	MESH:D000241
39728451	1376	1387	L-carnitine	Chemical	MESH:D002331
39728451	1393	1400	choline	Chemical	MESH:D002794
39728451	1440	1444	mice	Species	10090
39728451	1449	1452	STZ	Chemical	MESH:D013311
39728451	1461	1464	rat	Species	10116
39728451	1475	1477	DE	Disease	MESH:C000721848
39728451	1546	1549	SAL	Chemical	MESH:C009172
39728451	1605	1612	glucose	Chemical	MESH:D005947
39728451	1629	1638	glutamate	Chemical	MESH:D018698
39728451	1639	1648	glutamine	Chemical	MESH:D005973
39728451	1660	1665	lipid	Chemical	MESH:D008055
39728451	1717	1726	metabolic	Disease	MESH:D008659
39728451	1742	1744	DE	Disease	MESH:C000721848
39728451	1791	1794	SAL	Chemical	MESH:C009172
39728451	1886	1908	diabetic complications	Disease	MESH:D048909
39728451	Association	MESH:D000241	MESH:C000721848
39728451	Association	MESH:D005973	MESH:D018698
39728451	Association	MESH:C009172	MESH:D005973
39728451	Positive_Correlation	MESH:C009172	MESH:D005947
39728451	Association	MESH:D002794	MESH:C000721848
39728451	Positive_Correlation	MESH:D013311	MESH:C000721848
39728451	Association	MESH:D009711	MESH:D008659
39728451	Association	MESH:D005973	MESH:C000721848
39728451	Association	MESH:D001224	MESH:D008659
39728451	Negative_Correlation	MESH:C009172	MESH:C000721848
39728451	Association	MESH:D019298	MESH:C000721848
39728451	Association	MESH:D018698	MESH:D008659
39728451	Association	MESH:D005973	MESH:D008659
39728451	Association	MESH:C009172	MESH:D008659
39728451	Negative_Correlation	MESH:C009172	MESH:D048909
39728451	Association	MESH:D008055	MESH:D008659
39728451	Association	MESH:C009172	MESH:D018698
39728451	Association	MESH:D005947	MESH:D008659
39728451	Association	MESH:D002331	MESH:C000721848
39728451	Association	MESH:C009172	MESH:D008055
39728451	Association	MESH:D002331	MESH:D008659
39728451	Association	MESH:D002794	MESH:D008659

